FDA Clears IND for CSPC’s Monthly Octreotide in U.S. Acromegaly Trial

CSPC Pharmaceutical Group has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for SYHX2008, a long-acting octreotide injection for acromegaly. The milestone marks CSPC’s entry into U.S. clinical development and extends the global reach of its peptide therapeutics portfolio. SYHX2008 is already in Phase III trials in China.

Rare Endocrine Disorder with High Burden

Acromegaly, most often caused by a pituitary adenoma, results from chronic overproduction of growth hormone. Without treatment, patients face serious cardiovascular, metabolic, respiratory, and musculoskeletal complications. Octreotide, a somatostatin analog, remains a standard first-line therapy, suppressing growth hormone secretion and normalizing insulin-like growth factor-1 (IGF-1) levels.

Long-Acting Formulation Targets Convenience and Control

SYHX2008 leverages CSPC’s proprietary long-acting delivery platform. Following subcutaneous injection, the formulation forms a gel depot that gradually releases octreotide, enabling sustained exposure with once-monthly dosing.

Supplied in a prefilled syringe, the product allows patient self-administration at home, potentially improving treatment adherence while avoiding risks associated with intramuscular injections. The formulation utilizes highly biocompatible excipients to support controlled drug release over an extended period.

Clinical Data and Program Status

CSPC reports that SYHX2008 begins exerting therapeutic effects within one week of administration and does not require prior short-acting octreotide therapy. Clinical studies suggest biochemical control rates may exceed those reported with currently marketed octreotide microsphere formulations, though detailed efficacy results have not yet been disclosed.

Comprehensive safety data from ongoing studies have also not yet been reported. Phase III studies continue in China, while U.S. trials will now proceed under FDA authorization for patients with acromegaly.

Strategic Importance Beyond Acromegaly

The IND clearance underscores CSPC’s growing capabilities in long-acting drug delivery and strengthens its position in the global peptide therapeutics market. The milestone also highlights the potential of the company’s long-acting injection platform, which could support future applications across chronic endocrine disorders that require long-term treatment and sustained disease control.

Next Milestones in Global Program

With Phase III data pending in China, CSPC is expected to initiate U.S. clinical development to support future regulatory expansion. Upcoming milestones include additional efficacy, safety, and pharmacokinetic readouts, alongside potential regulatory discussions on global commercialization pathways.

If ongoing studies confirm its clinical profile, SYHX2008 could offer a more convenient long-acting octreotide option through monthly subcutaneous self-administration without the need for treatment initiation with short-acting octreotide.

What This Means for Patients

For people living with acromegaly, SYHX2008 may offer a more convenient treatment option if it successfully completes clinical development. The investigational therapy is administered once monthly through a subcutaneous injection and may be self-administered using a prefilled syringe, reducing the need for clinic visits associated with some currently available long-acting formulations.

Early clinical findings suggest the treatment begins working within one week and may not require initial treatment with short-acting octreotide injections. If ongoing studies confirm its efficacy and safety, SYHX2008 could help simplify long-term disease management and improve treatment adherence for patients requiring lifelong therapy.

Reference

OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.